[Edaily Reporter LEE YOU-RIM ] Friday, the 2nd, is expected to be chilly, with minimum temperatures across the country dropping to 5 degrees.
'A Morning That Calls for a Jacket or Hoodie' (Seoul=Yonhap News) Reporter Kim Ju-hyung = On the morning of October 1, citizens are commuting to work amid the chilly weather on Gwanghwamun Street in Jongno-gu, Seoul. October 1, 2026
According to the Korea Meteorological Administration on the 1st, temperatures will begin to drop starting this afternoon as cold air flows in from the north, and strong winds through tomorrow will make it feel even colder.
Strong winds with gusts of around 55 km/h are expected in most parts of the country through the afternoon, and winds in mountainous areas will intensify to around 70 km/h.
Morning lows are forecast to range from 5 to 14 degrees, while daytime highs are expected to be between 19 and 23 degrees.
Morning lows by region are as follows: △Seoul 11°C △Incheon 11°C △Suwon 11°C △Chuncheon 7°C △Gangneung 10°C △Cheongju 10°C △Daejeon 10°C △Sejong 9°C △Jeonju 10°C △Gwangju 12°C △Daegu 10°C △Busan 14°C △Ulsan 12°C, △Changwon 13°C, and △Jeju 18°C.
The temperature difference between day and night will be significant, around 15 degrees. Frost is expected in some inland areas of Gangwon Province.
In the morning, light rain (less than 0.1 mm) is expected in parts of the Chungcheong and Jeolla regions, North Gyeongsang Province, the northwestern inland areas of South Gyeongsang Province, and Jeju Island.
Waves will reach 0.5 to 2.5 meters in the East Sea and 0.5 to 1.0 meters in the West and South Seas.
SAMSUNG BIOLOGICS(207940)has announced plans to respond strictly, in accordance with the law and established principles, to any illegal or unlawful acts related to the conflict with the labor union ov…
“‘Jjarur,’ a jajangmyeon-flavored instant noodle made with lard, sold 10 million servings within 100 days of its launch. The company aims to surpass 10 billion won in sales by the end of the year.” (K…
NeoImmuneTech, Inc.(950220)announced on the 7th that its U.S. partner, Tolerance Bio, presented “NT-I7” (epineptakin alfa), a long-acting interleukin-7 (IL-7) candidate, as a key clinical pipeline for…